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Aspirin and Extended-Release Dipyridamole versus
Clopidogrel for Recurrent StrokePrevention Regimen for
Effectively Avoiding Second Strokes(PRoFESS) Study Group.

Why is this study of clinical importance?
Stroke is the second leading cause of death in the
world. However, nonfatal stroke is approximately 3 times as
common as fatal stroke; therefore, secondary prevention to
prevent stroke is a critical treatment priority. Clinical trials
have proved the efficacy of antiplatelet agents for the
prevention of recurrent stroke after non-cardioembolic stroke.
Antiplatelet options for the prevention of recurrent stroke
includes aspirin (50 mg to 325 mg per day), the combination
of low dose aspirin and extended-release dipyridamole, and
clopidogrel alone. Aspirin has shown to reduce the stroke
recurrence risk by about 23% as compared with placebo.
Clopidogrel has shown 8% relative risk reduction of stroke
recurrence, as compared with aspirin, among stroke patients.
Studies of aspirin plus extended-release dipyridamole have
suggested relative risk reductions of 20 to 23% as compared
with aspirin alone. Combination of two antiplatelet agents
with different mechanisms of action maybe more effective in
preventing recurrent stroke than either is alone, increased
bleeding may result.
There is no guideline for using one of these therapies
over the other. Thus, this trial was aimed to compare the
relative efficacy and safety of aspirin plus extended-release
dipyridamole with that of clopidogrel among patients who
had a recent ischaemic stroke.

Who were the participants?
A total of 20,333 patients were enrolled from 695centers
in 35 countries including Asian contributions. The inclusion
criteria were a recent ischaemic stroke (within <90 days before
randomization), defined by symptoms persisting for more than
24 hours or symptoms of a shorter duration but with evidence
of a recent brain infarction on a computed tomographic scan or
magnetic resonance imaging; clinical and neurologic stability
before randomization; and an age of 55 years or older. Patients
were excluded if they had contraindications to one of the
antiplatelet agents or were otherwise unsuitable for
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randomization. There was protocol amendment to include
younger patients (50 to 54years of age) or those with less recent
strokes (within 90 to 120 days before randomization) if they
also had at least two additional vascular risk factors.

What was the intervention?
The Prevention Regimen for Effectively Avoiding
Second Strokes (PRoFESS) trial was a 2-by-2 factorial,
double-blind, active and placebo-controlled study. Eligible and
consenting patients were randomly assigned, through a central
telephone randomization system, to receive either aspirin (25
mg) plus extended-release dipyridamole (200 mg) twice daily
or clopidogrel (75 mg daily) and telmisartan (80mg daily) or
placebo. Patients were evaluated in the hospital at the time of
discharge or at 1 week after discharge and then at 1, 3, and 6
months and every6 months thereafter. The mean duration of
follow-up was 2.5 years (range, 1.5 to 4.4); 1495 patients
(7.4%) died during the study and 125 patients (0.6% in each
treatment group) were lost to follow-up.

What was the outcome?
The primary outcome was recurrent stroke of any type.
The secondary outcome was a composite of stroke, myocardial
infarction, or death from vascular causes. Recurrent stroke
occurred in 916 patients (9.0%) receiving ASA-ERDP and in
898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01;
95% confidence interval [CI], 0.92 to 1.11).
Premature discontinuation of the study drug was
significantly more frequent among patients receiving
aspirin plus extended-release dipyridamole (2961 [29.1%]
patients) than among those receiving clopidogrel (2290
[22.6%], P<0.001).

What were the conclusions?
This trial concluded that similar rates of recurrent
stroke with ASA-ERDP and with clopidogrel. There is no
evidence that either of the two treatments was superior to the
other in the prevention of recurrent stroke.

How does this impact us?
The large number and international representation
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of patients, who were from 35 countries enhances the
generalizability of this trial. In patients with a noncardioembolic ischaemic stroke the risks of recurrent
stroke are similar with aspirin plus extended release
dipyridamole and with clopidogrel. It appears that for a
patient with stroke requiring secondary prevention
Clopidrogrel alone, or Aspirin combined with slow
release Dipyridamole are all acceptable options with no
clear superiority of one to another. In a developing nation
like Pakistan these decisions must be based by keeping in
view finance (these are life long drugs), compliance
issues, individual susceptibilities and reaction to any
component of drug combination.
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